Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Herbst

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysAlan Sandler, Roy Herbst
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Personalized therapyPeter Ujhazy, Roy Herbst
Clinical Advances in Hematology & Oncology : H&O|December 5, 2006
Angiogenesis inhibition in the treatment of lung cancerEverett Vokes, Roy Herbst, Alan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach, Monique Nilsson, George Blumenschein, et al.
Clinical Lung Cancer|March 5, 2010
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trialsRalph G Zinner, Silvia Novello, Guangbin Peng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 16, 2011
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancerAlan Sandler, Charles Graham, Maria Baggstrom, et al.
Molecular Cancer Therapeutics|August 24, 2012
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonistVivek Subbiah, Robert E Brown, Jamie Buryanek, et al.
Cancer|January 24, 2009
The changing face of phase 1 cancer clinical trials: new challenges in study requirementsBarbara S Craft, Razelle Kurzrock, Xiudong Lei, et al.
Frontiers in Oncology|July 26, 2021
A Network Meta-Analysis of Cancer Immunotherapies <i>Versus</i> Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 ExpressionRoy Herbst, Jacek Jassem, Seye Abogunrin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2010
Molecular origins of lung cancer: prospects for personalized prevention and therapyEric B Haura, D Ross Camidge, Karen Reckamp, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysAlan Sandler, Roy Herbst
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Personalized therapyPeter Ujhazy, Roy Herbst
Clinical Advances in Hematology & Oncology : H&O|December 5, 2006
Angiogenesis inhibition in the treatment of lung cancerEverett Vokes, Roy Herbst, Alan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach, Monique Nilsson, George Blumenschein, et al.
Clinical Lung Cancer|March 5, 2010
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trialsRalph G Zinner, Silvia Novello, Guangbin Peng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 16, 2011
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancerAlan Sandler, Charles Graham, Maria Baggstrom, et al.
Molecular Cancer Therapeutics|August 24, 2012
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonistVivek Subbiah, Robert E Brown, Jamie Buryanek, et al.
Cancer|January 24, 2009
The changing face of phase 1 cancer clinical trials: new challenges in study requirementsBarbara S Craft, Razelle Kurzrock, Xiudong Lei, et al.
Frontiers in Oncology|July 26, 2021
A Network Meta-Analysis of Cancer Immunotherapies <i>Versus</i> Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 ExpressionRoy Herbst, Jacek Jassem, Seye Abogunrin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2010
Molecular origins of lung cancer: prospects for personalized prevention and therapyEric B Haura, D Ross Camidge, Karen Reckamp, et al.
Pageof 4